Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals has entered a clinical trial collaboration and supply agreement with Bayer to test its investigational KAT6 inhibitor OP-3136 with Bayer’s androgen receptor inhibitor NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer.
The planned Phase 1b/2 study will evaluate safety, tolerability, and preliminary anti-tumor activity of the combination in approximately 36 patients with mCRPC and is expected to start in the second half of 2026. Bayer will supply darolutamide, while Olema will lead the trial.
All clinical data and inventions related to the combination will be jointly owned, and Olema will retain full global commercial and marketing rights to OP-3136. This is the first clinical collaboration for OP-3136 and extends its development beyond breast cancer into prostate cancer.
Olema Pharmaceuticals reported encouraging preliminary Phase 1 data for OP-3136, its oral KAT6 inhibitor, in advanced solid tumors. In 32 heavily pretreated patients across ER+/HER2- breast, metastatic castration-resistant prostate, and metastatic non-small cell lung cancers, doses from 2 mg to 45 mg once daily were evaluated.
OP-3136 was well-tolerated with no dose-limiting toxicities, no grade 4 or 5 treatment-related adverse events, and no discontinuations due to treatment-related events. Among 19 response-evaluable patients, tumor shrinkage occurred in 13, including 3 partial responses, 2 of which were confirmed. Eleven patients remain on treatment, with the longest treatment duration at 62 weeks. OP-3136 showed rapid, sustained reduction of its histone target and predictable, dose-proportional pharmacokinetics, supporting continued monotherapy and combination development.
Olema Pharmaceuticals: Bain Capital Life Sciences Opportunities IV, L.P. filed an amendment to its Schedule 13G/A reporting that, as of March 31, 2026, it beneficially owned 2,960,036 shares and a pre-funded warrant exercisable for 4,513,202 shares, together representing approximately 8.2% of the common stock.
The filing states 7,473,238 shares are held with shared voting and dispositive power and that the pre-funded warrant cannot be exercised to exceed a 9.99% beneficial ownership limitation. Shares outstanding were cited as 87,156,961 as of March 11, 2026.
Janus Henderson Group plc reports beneficial ownership of 7,108,488 shares of Olema Pharmaceuticals, Inc. common stock, representing 8.2% of the class. The filing states the Asset Managers exercise shared voting and shared dispositive power over those shares. The Asset Managers act on behalf of multiple Managed Portfolios and the filing notes that the Asset Managers do not have the right to receive dividends or sale proceeds from certain securities held in those Managed Portfolios and disclaim ownership associated with those rights.
Olema Pharmaceuticals reported a larger quarterly loss as it invests heavily in cancer drug development, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss was $53.1 million compared with $30.4 million a year earlier, driven mainly by higher research and development expenses of $49.2 million and general and administrative expenses of $8.8 million.
Total assets were $530.6 million, including $505.3 million in cash, cash equivalents and marketable securities. Operating cash outflow was $46.0 million, largely offset by $41.9 million of net proceeds from an at-the-market stock program. Management believes existing cash, securities and available debt capacity will fund the current operating plan for at least 12 months. As of May 7, 2026, common shares outstanding were 87.3 million, excluding 13.6 million shares issuable upon exercise of pre-funded warrants.
Olema Oncology reported first quarter 2026 results highlighted by heavy investment in late-stage breast cancer programs and a strong cash position. Cash, cash equivalents, and marketable securities were $505.3 million as of March 31, 2026. Net loss was $53.1 million, compared with $30.4 million a year earlier, reflecting increased spending on clinical development and corporate activities.
GAAP R&D expenses rose to $49.2 million from $30.6 million, while GAAP G&A expenses increased to $8.8 million from $4.2 million, driven in part by higher non-cash stock-based compensation. Non-GAAP R&D and G&A expenses were $42.7 million and $5.2 million, respectively. The company expects top-line data from its pivotal Phase 3 OPERA-01 trial this fall, continues enrollment in the Phase 3 OPERA-02 trial, and plans for an anticipated first commercial launch next year.
Olema Pharmaceuticals, Inc. entered a seven-year lease with KR Oyster Point II, LLC for a new headquarters totaling approximately 38,176 square feet across two floors in South San Francisco. The company plans to relocate its corporate headquarters to this space by December 2026 as existing San Francisco leases expire between December 2026 and January 2027.
The Lease sets total base rent of $12,361,188.00 for Phase I and $6,145,463.76 for Phase II during the initial term, net of rent abatement. Olema must provide a cash security deposit of $427,546.80 and may terminate once at month 60 by paying a $1,716,240.96 fee. The agreement includes a five-year extension option and a right of first offer on additional space, while the landlord funds specified build-out work and can terminate if Olema fails to cure certain breaches.
Olema Pharmaceuticals director Raman Prakash received two stock option grants as equity compensation. The awards cover a combined 27,061 shares of common stock at an exercise price of $14.59 per share, expiring on April 27, 2036.
Options on 24,150 shares vest in full on June 11, 2026, while options on 2,911 shares vest in 36 equal monthly installments starting April 28, 2026. All vesting is conditioned on Prakash’s continuous service with the company.
Olema Pharmaceuticals, Inc. director Raman Prakash has filed an initial insider ownership report. This filing establishes his status as a reporting person for the company and, based on the provided data, does not list any share purchases, sales, or other transactions.